AVROBIO Inc logo

AVRO - AVROBIO Inc Share Price

$22.78 2.0  9.6%

Last Trade - 17/01/20

Sector
Healthcare
Size
Mid Cap
Market Cap £554.6m
Enterprise Value £395.9m
Revenue £n/a
Position in Universe 2735th / 6415
Bullish
Bearish
Unlock AVRO Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

AVRO Revenue Unlock AVRO Revenue

Net Income

AVRO Net Income Unlock AVRO Revenue

Normalised EPS

AVRO Normalised EPS Unlock AVRO Revenue

PE Ratio Range

AVRO PE Ratio Range Unlock AVRO Revenue

Dividend Yield Range

AVRO Dividend Yield Range Unlock AVRO Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
AVRO EPS Forecasts Unlock AVRO Revenue
Profile Summary

AVROBIO, Inc. is a phase II clinical stage gene therapy company. The Company is focused on developing curative ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose. Its gene therapies employ hematopoietic stem cells that are extracted from the patient and then modified with lentiviral vectors to insert a functional copy of the gene that is defective in the target disease. Its product pipeline includes AVR-RD-01, AVR-RD-02, AVR-RD-03 and AVR-RD-04. The Company is developing AVR-RD-01 for the treatment of Fabry disease. AVR-RD-02 is the Company’s gene therapy for Gaucher disease. AVR-RD-03 is being developed for the treatment of Pompe disease. The Company is developing AVR-RD-04 for the treatment of patients with cystinosis.

Directors
Last Annual December 31st, 2018
Last Interim September 30th, 2019
Incorporated November 17, 2015
Public Since June 21, 2018
No. of Shareholders: 16
No. of Employees: 73
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 31,667,901
Free Float (0.0%)
Eligible for
ISAs
SIPPs
AVRO Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for AVRO
Upcoming Events for AVRO
Similar to AVRO
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.